JPMorgan Mid Cap Growth Fund
Schedule of Portfolio Investments as of March 31, 2023
(Unaudited)
THE “UNAUDITED MUTUAL FUNDS HOLDINGS” LIST (“the List”) IS TO BE USED FOR REPORTING PURPOSES ONLY. IT IS NOT TO BE REPRODUCED FOR USE AS ADVERTISING OR SALES LITERATURE WITH THE GENERAL PUBLIC. The list is submitted for the general information of the shareholders of the Fund. It is not authorized for distribution to prospective investors in the Fund unless preceded or accompanied by a prospectus. The list has been created from the books and records of the Fund. Holdings are available 60 days after the fund’s fiscal quarter, using a trade date accounting convention, by contacting the appropriate service center. The list is subject to change without notice. The list is for informational purposes only and is not intended as an offer or solicitation with respect to the purchase or sale of any security. |
JPMorgan Asset Management is the marketing name for the asset management business of J.P. Morgan Chase & Co. |
J.P. Morgan Distribution Services, Inc., member FINRA. |
© J.P. Morgan Chase & Co., 2023. |
JPMorgan Mid Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited)
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited)
INVESTMENTS | SHARES (000) | VALUE ($000) |
Common Stocks — 97.3% | ||
Aerospace & Defense — 0.8% | ||
HEICO Corp., Class A | 490 | 66,609 |
Banks — 0.4% | ||
East West Bancorp, Inc. | 555 | 30,798 |
Beverages — 0.8% | ||
Constellation Brands, Inc., Class A | 280 | 63,348 |
Biotechnology — 5.5% | ||
Alnylam Pharmaceuticals, Inc. * | 469 | 94,002 |
Exact Sciences Corp. * (a) | 1,179 | 79,944 |
Exelixis, Inc. * | 2,951 | 57,266 |
Natera, Inc. * | 1,166 | 64,749 |
Neurocrine Biosciences, Inc. * | 614 | 62,182 |
Sarepta Therapeutics, Inc. * | 286 | 39,416 |
Seagen, Inc. * | 297 | 60,080 |
457,639 | ||
Broadline Retail — 0.5% | ||
Etsy, Inc. * (a) | 351 | 39,116 |
Building Products — 2.1% | ||
Trane Technologies plc | 963 | 177,085 |
Capital Markets — 7.3% | ||
Ares Management Corp. | 1,107 | 92,382 |
FactSet Research Systems, Inc. | 189 | 78,228 |
LPL Financial Holdings, Inc. | 471 | 95,285 |
Morningstar, Inc. | 235 | 47,789 |
MSCI, Inc. | 243 | 135,738 |
S&P Global, Inc. | 213 | 73,428 |
Tradeweb Markets, Inc., Class A | 1,060 | 83,775 |
606,625 | ||
Commercial Services & Supplies — 2.8% | ||
Cintas Corp. | 117 | 54,175 |
Copart, Inc. * | 2,352 | 176,914 |
231,089 | ||
Communications Equipment — 1.3% | ||
Arista Networks, Inc. * | 667 | 111,964 |
Construction & Engineering — 3.6% | ||
AECOM | 713 | 60,087 |
Quanta Services, Inc. | 1,121 | 186,748 |
Valmont Industries, Inc. | 160 | 51,190 |
298,025 | ||
Distributors — 0.4% | ||
Pool Corp. | 94 | 32,256 |
Diversified Consumer Services — 0.6% | ||
Bright Horizons Family Solutions, Inc. * | 680 | 52,350 |
JPMorgan Mid Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
INVESTMENTS | SHARES (000) | VALUE ($000) |
Common Stocks — continued | ||
Electrical Equipment — 2.3% | ||
AMETEK, Inc. | 690 | 100,290 |
Hubbell, Inc. | 365 | 88,854 |
189,144 | ||
Electronic Equipment, Instruments & Components — 3.4% | ||
Jabil, Inc. | 814 | 71,766 |
Keysight Technologies, Inc. * | 476 | 76,962 |
Teledyne Technologies, Inc. * | 146 | 65,179 |
Zebra Technologies Corp., Class A * | 230 | 73,136 |
287,043 | ||
Energy Equipment & Services — 0.7% | ||
TechnipFMC plc (United Kingdom) * | 4,119 | 56,218 |
Entertainment — 1.1% | ||
Take-Two Interactive Software, Inc. * | 743 | 88,614 |
Financial Services — 1.2% | ||
Global Payments, Inc. | 468 | 49,300 |
Remitly Global, Inc. * | 3,275 | 55,510 |
104,810 | ||
Ground Transportation — 1.0% | ||
Old Dominion Freight Line, Inc. | 238 | 80,997 |
Health Care Equipment & Supplies — 8.6% | ||
Align Technology, Inc. * | 204 | 68,091 |
Cooper Cos., Inc. (The) | 215 | 80,425 |
Dexcom, Inc. * | 1,428 | 165,932 |
Hologic, Inc. * | 978 | 78,893 |
IDEXX Laboratories, Inc. * | 147 | 73,275 |
Insulet Corp. * | 380 | 121,271 |
Novocure Ltd. * | 161 | 9,702 |
ResMed, Inc. | 390 | 85,370 |
Shockwave Medical, Inc. * | 153 | 33,123 |
716,082 | ||
Health Care Providers & Services — 3.0% | ||
Acadia Healthcare Co., Inc. * | 969 | 69,998 |
Amedisys, Inc. * | 549 | 40,434 |
Centene Corp. * | 1,205 | 76,170 |
McKesson Corp. | 170 | 60,458 |
247,060 | ||
Hotels, Restaurants & Leisure — 5.5% | ||
Aramark | 1,506 | 53,913 |
Booking Holdings, Inc. * | 18 | 46,834 |
Chipotle Mexican Grill, Inc. * | 89 | 151,250 |
Domino's Pizza, Inc. | 96 | 31,835 |
JPMorgan Mid Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
INVESTMENTS | SHARES (000) | VALUE ($000) |
Common Stocks — continued | ||
Hotels, Restaurants & Leisure — continued | ||
Hilton Worldwide Holdings, Inc. | 1,024 | 144,230 |
Royal Caribbean Cruises Ltd. * | 463 | 30,261 |
458,323 | ||
Household Durables — 1.1% | ||
Garmin Ltd. | 476 | 48,040 |
Helen of Troy Ltd. * | 481 | 45,766 |
93,806 | ||
Insurance — 1.3% | ||
Progressive Corp. (The) | 763 | 109,151 |
IT Services — 1.4% | ||
Globant SA * | 70 | 11,385 |
MongoDB, Inc. * | 453 | 105,694 |
117,079 | ||
Life Sciences Tools & Services — 4.8% | ||
10X Genomics, Inc., Class A * | 628 | 35,051 |
Agilent Technologies, Inc. | 1,036 | 143,260 |
Maravai LifeSciences Holdings, Inc., Class A * | 1,677 | 23,497 |
Mettler-Toledo International, Inc. * | 69 | 105,623 |
West Pharmaceutical Services, Inc. | 267 | 92,524 |
399,955 | ||
Machinery — 2.8% | ||
Ingersoll Rand, Inc. | 1,261 | 73,391 |
ITT, Inc. | 934 | 80,615 |
Toro Co. (The) | 733 | 81,460 |
235,466 | ||
Media — 1.6% | ||
Trade Desk, Inc. (The), Class A * | 2,232 | 135,979 |
Metals & Mining — 0.6% | ||
Freeport-McMoRan, Inc. | 1,243 | 50,830 |
Oil, Gas & Consumable Fuels — 3.1% | ||
Antero Resources Corp. * (a) | 1,106 | 25,539 |
Cheniere Energy, Inc. | 964 | 151,851 |
EOG Resources, Inc. | 716 | 82,131 |
259,521 | ||
Pharmaceuticals — 1.4% | ||
Jazz Pharmaceuticals plc * | 355 | 51,959 |
Royalty Pharma plc, Class A | 1,721 | 62,021 |
113,980 | ||
Professional Services — 0.9% | ||
Equifax, Inc. | 393 | 79,718 |
Semiconductors & Semiconductor Equipment — 4.8% | ||
Advanced Micro Devices, Inc. * | 486 | 47,633 |
JPMorgan Mid Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
INVESTMENTS | SHARES (000) | VALUE ($000) |
Common Stocks — continued | ||
Semiconductors & Semiconductor Equipment — continued | ||
Entegris, Inc. | 831 | 68,178 |
Marvell Technology, Inc. | 1,078 | 46,676 |
Monolithic Power Systems, Inc. | 121 | 60,777 |
Rambus, Inc. * | 635 | 32,550 |
SolarEdge Technologies, Inc. * | 244 | 74,235 |
Teradyne, Inc. | 385 | 41,377 |
Wolfspeed, Inc. * (a) | 505 | 32,775 |
404,201 | ||
Software — 14.2% | ||
Cadence Design Systems, Inc. * | 822 | 172,744 |
Clear Secure, Inc., Class A (a) | 832 | 21,774 |
Confluent, Inc., Class A * (a) | 2,497 | 60,104 |
Crowdstrike Holdings, Inc., Class A * | 832 | 114,236 |
DocuSign, Inc. * | 773 | 45,061 |
Five9, Inc. * | 508 | 36,711 |
HashiCorp, Inc., Class A * | 1,785 | 52,292 |
HubSpot, Inc. * | 267 | 114,206 |
Palo Alto Networks, Inc. * | 671 | 133,967 |
Procore Technologies, Inc. * (a) | 1,000 | 62,600 |
Synopsys, Inc. * | 483 | 186,598 |
Workday, Inc., Class A * | 326 | 67,321 |
Zoom Video Communications, Inc., Class A * | 1,000 | 73,847 |
Zscaler, Inc. * | 342 | 39,975 |
1,181,436 | ||
Specialty Retail — 4.8% | ||
AutoZone, Inc. * | 47 | 116,076 |
Burlington Stores, Inc. * | 363 | 73,463 |
National Vision Holdings, Inc. * | 957 | 18,035 |
Ross Stores, Inc. | 692 | 73,434 |
Tractor Supply Co. | 497 | 116,707 |
397,715 | ||
Textiles, Apparel & Luxury Goods — 0.9% | ||
Lululemon Athletica, Inc. * | 219 | 79,765 |
Trading Companies & Distributors — 0.7% | ||
Air Lease Corp. | 1,531 | 60,255 |
Total Common Stocks (Cost $6,492,243) | 8,114,052 | |
Short-Term Investments — 4.0% | ||
Investment Companies — 3.3% | ||
JPMorgan Prime Money Market Fund Class IM Shares, 4.96% (b) (c) (Cost $273,230) | 273,151 | 273,233 |
Investment of Cash Collateral from Securities Loaned — 0.7% | ||
JPMorgan Securities Lending Money Market Fund Agency SL Class Shares, 5.04% (b) (c) | 51,902 | 51,912 |
JPMorgan Mid Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
INVESTMENTS | SHARES (000) | VALUE ($000) |
Short-Term Investments — continued | ||
Investment of Cash Collateral from Securities Loaned — continued | ||
JPMorgan U.S. Government Money Market Fund Class IM Shares, 4.68% (b) (c) | 10,464 | 10,464 |
Total Investment of Cash Collateral from Securities Loaned (Cost $62,388) | 62,376 | |
Total Short-Term Investments (Cost $335,618) | 335,609 | |
Total Investments — 101.3% (Cost $6,827,861) | 8,449,661 | |
Liabilities in Excess of Other Assets — (1.3)% | (105,144 ) | |
NET ASSETS — 100.0% | 8,344,517 | |
Percentages indicated are based on net assets. |
* | Non-income producing security. |
(a) | The security or a portion of this security is on loan at March 31, 2023. The total value of securities on loan at March 31, 2023 is $62,155. |
(b) | Investment in an affiliated fund, which is registered under the Investment Company Act of 1940, as amended, and is advised by J.P. Morgan Investment Management Inc. |
(c) | The rate shown is the current yield as of March 31, 2023. |
JPMorgan Mid Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
(Dollar values in thousands)
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
(Dollar values in thousands)
A. Valuation of Investments — Investments are valued in accordance with U.S. generally accepted accounting principles (“GAAP”) and the Fund's valuation policies set forth by, and under the supervision and responsibility of, the Board of Trustees of the Trust (the “Board”), which established the following approach to valuation, as described more fully below: (i) investments for which market quotations are readily available shall be valued at their market value and (ii) all other investments for which market quotations are not readily available shall be valued at their fair value as determined in good faith by the Board.
Under Section 2(a)(41) of the Investment Company Act of 1940, the Board is required to determine fair value for securities that do not have readily available market quotations. Under SEC Rule 2a-5 (Good Faith Determinations of Fair Value), the Board may designate the performance of these fair valuation determinations to a valuation designee. The Board has designated the Adviser as the “Valuation Designee” to perform fair valuation determinations for the Funds on behalf of the Board subject to appropriate oversight by the Board. The Adviser, as Valuation Designee, leverages the J.P. Morgan Asset Management Americas Valuation Committee (“AVC”) to help oversee and carry out the policies for the valuation of Investments held in the Funds. The Adviser, as Valuation Designee, remains responsible for the valuation determinations.
This oversight by the AVC includes monitoring the appropriateness of fair values based on results of ongoing valuation oversight including, but not limited to, consideration of macro or security specific events, market events, and pricing vendor and broker due diligence. The Administrator is responsible for discussing and assessing the potential impacts to the fair values on an ongoing basis, and, at least on a quarterly basis, with the AVC and the Board.
Equities and other exchange-traded instruments are valued at the last sale price or official market closing price on the primary exchange on which the instrument is traded before the net asset values (“NAV”) of the Fund are calculated on a valuation date.
Investments in open-end investment companies (“Underlying Funds”) are valued at each Underlying Fund’s NAV per share as of the report date.
Valuations reflected in this report are as of the report date. As a result, changes in valuation due to market events and/or issuer-related events after the report date and prior to issuance of the report are not reflected herein.
The various inputs that are used in determining the valuation of the Fund's investments are summarized into the three broad levels listed below.
•
Level 1 — Unadjusted inputs using quoted prices in active markets for identical investments.
•
Level 2 — Other significant observable inputs including, but not limited to, quoted prices for similar investments, inputs other than quoted prices that are observable for investments (such as interest rates, prepayment speeds, credit risk, etc.) or other market corroborated inputs.
•
Level 3 — Significant inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Fund's assumptions in determining the fair value of investments).
A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input, both individually and in the aggregate, that is significant to the fair value measurement. The inputs or methodology used for valuing instruments are not necessarily an indication of the risk associated with investing in those instruments.
The following table represents each valuation input as presented on the Schedule of Portfolio Investments ("SOI"):
Level 1 Quoted prices | Level 2 Other significant observable inputs | Level 3 Significant unobservable inputs | Total | |
Total Investments in Securities (a) | $8,449,661 | $— | $— | $8,449,661 |
(a) | Please refer to the SOI for specifics of portfolio holdings. |
B. Investment Transactions with Affiliates — The Fund invested in Underlying Funds, which are advised by the Adviser. An issuer which is under common control with the Fund may be considered an affiliate. The Fund assumes the issuers listed in the table below to be affiliated
JPMorgan Mid Cap Growth Fund
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
(Dollar values in thousands)
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF March 31, 2023 (Unaudited) (continued)
(Dollar values in thousands)
issuers. The Underlying Funds’ distributions may be reinvested into such Underlying Funds. Reinvestment amounts are included in the purchases at cost amounts in the table below.
For the period ended March 31, 2023 | |||||||||
Security Description | Value at June 30, 2022 | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation/ (Depreciation) | Value at March 31, 2023 | Shares at March 31, 2023 | Dividend Income | Capital Gain Distributions |
JPMorgan Prime Money Market Fund Class IM Shares, 4.96% (a) (b) | $260,555 | $1,772,080 | $1,759,423 | $38 | $(17) | $273,233 | 273,151 | $5,430 | $— |
JPMorgan Securities Lending Money Market Fund Agency SL Class Shares, 5.04% (a) (b) | 53,864 | 676,000 | 678,000 | 59 | (11) | 51,912 | 51,902 | 2,571 | — |
JPMorgan U.S. Government Money Market Fund Class IM Shares, 4.68% (a) (b) | 6,877 | 317,139 | 313,552 | — | — | 10,464 | 10,464 | 368 | — |
Total | $321,296 | $2,765,219 | $2,750,975 | $97 | $(28) | $335,609 | $8,369 | $— | |
(a) | Investment in an affiliated fund, which is registered under the Investment Company Act of 1940, as amended, and is advised by J.P. Morgan Investment Management Inc. |
(b) | The rate shown is the current yield as of March 31, 2023. |